Tumors admixed with CCR2+ cells were smaller than those that were admixed with CCR2− cells, further supporting that the trained CCR2+ myeloid cells themselves are a primary effector cell in the anti-tumor mechanism (Fig. 7b). This evidence concerns the gene CCR2 and neoplasm.